With Trump's tariffs looming, is this really the appropriate time to load up on pharma stocks? And where does Cipla stand in ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment ...

Efforts to get Gilead’s experimental COVID-19 drug remdesivir to patients in badly-hit India are building after drug maker Cipla announced it had launched the drug in the country. The ...

The court ruled that Cipla’s antibiotic name ‘FURIZOME’ is too similar to rival Adcock Ingram’s ‘URIZONE,’ citing a risk of ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India.

Cipla's generic version of Abraxane receives final FDA approval, launching in the U.S. by September for cancer treatment.

New Delhi: The pharmaceutical major Cipla has got the go-ahead from the Subject Expert Committee (SEC) functional under the ...

Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol propionate ophthalmic suspension 0.

Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial.

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and ...

The firm stated that it is now set to introduce the product in the United States in H1FY26, earlier than anticipated.